TRICOR (fenofibrate) by AbbVie is peroxisome proliferator-activated receptor alpha agonists [moa]. First approved in 2004.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
TRICOR (fenofibrate) is an oral small-molecule fibrate approved in 2004 that works as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist. It is used to treat dyslipidemia, particularly elevated triglycerides and low HDL cholesterol. The drug reduces triglyceride production in the liver and increases HDL clearance.
As LOE approaches, brand teams face contraction; focus shifts to managed decline and cost optimization rather than growth initiatives.
Peroxisome Proliferator-activated Receptor alpha Agonists
Peroxisome Proliferator Receptor alpha Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
Fenofibrate for Prevention of DR Worsening
Fenofibrate for Patients With COVID-19 Requiring Hospitalization
Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)
Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy
Worked on TRICOR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on TRICOR in 2024 positions you in the sunset phase of a product lifecycle, with career growth constrained by LOE pressure and declining revenue. Roles emphasize managed decline, cost management, and formulary access rather than growth or innovation.